PT  - JOURNAL ARTICLE
AU  - Derlin, Thorsten
AU  - Widjaja, Liam
AU  - Werner, Rudolf A.
AU  - Bengel, Frank M.
TI  - <sup>177</sup>Lu-PSMA for Extended Treatment of Metastatic Castration-Resistant Prostate Cancer
AID  - 10.2967/jnumed.122.264293
DP  - 2023 Jan 01
TA  - Journal of Nuclear Medicine
PG  - 54--58
VI  - 64
IP  - 1
4099  - http://jnm.snmjournals.org/content/64/1/54.short
4100  - http://jnm.snmjournals.org/content/64/1/54.full
SO  - J Nucl Med2023 Jan 01; 64
AB  - Our objective was to evaluate the feasibility, additional benefit, and toxicity of extending prostate-specific membrane antigen (PSMA)–targeted radioligand therapy in patients with metastatic castration-resistant prostate cancer. Methods: From 208 patients treated with 177Lu-PSMA every 6–8 wk, 26 who had not progressed and not experienced grade 3 or higher toxicity after 6 cycles continued to receive 177Lu-PSMA until disease progression, complete remission, or removal from treatment because of toxicity or patient preference. Response rates, the additional benefit of treatment extension, and toxicity were assessed. Results: During treatment extension (≤13 cycles), 50% of patients achieved an additional prostate-specific antigen decline (−52% ± 34%; range, −1% to −100%), with 8% of patients achieving a congruent prostate-specific antigen–based and imaging-based complete response. Median progression-free survival was 450 d. Acute toxicity, including myelosuppression, was mild (≤grade 2). Xerostomia and chronic kidney disease became more common with repetitive dosing. Conclusion: Extension of 177Lu-PSMA treatment is feasible and effective in metastatic castration-resistant prostate cancer.